scPharmaceuticals Inc. (SCPH) Stock Analysis & Investment Frameworks
scPharmaceuticals Inc. (SCPH) stock analysis on Invetso. Review scPharmaceuticals Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
scPharmaceuticals Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
scPharmaceuticals Inc. Key Financial Metrics
- Market Cap: $302.20M
- Revenue: $36.33M
- ROE: -336.97%
- ROIC: -69.74%
- Dividend Yield: N/A
About scPharmaceuticals Inc.
scPharmaceuticals Inc. is a pharmaceutical firm dedicated to developing and commercializing a variety of medicinal products. Its primary investigational therapy, FUROSCIX, is a specialized formulation of furosemide delivered through an on-body infusor, intended for managing congestion in heart failure patients. The company's pipeline also encompasses scCeftriaxone, an antibiotic aimed at treating infections caused by both gram-positive and gram-negative bacteria, as well as the scCarbapenem program, another antibiotic designed for gram-negative bacterial infections. Additionally, scPharmaceuticals has entered into a collaboration agreement with West Pharmaceutical Services, Inc. for the advancement of a single-use SmartDose device. Founded in 2013, the company's main operations are based in Burlington, Massachusetts.